List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis - Overview
Familial Adenomatous Polyposis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Emtora Biosciences
FunPep Co Ltd
GLW Pharma
Johnson & Johnson
Recursion Pharmaceuticals Inc
Shanghai Haishi Biopharmaceutical Co Ltd
Stemsynergy Therapeutics Inc
TherapyX Inc
Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis - Drug Profiles
(eflornithine hydrochloride + sulindac) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXONC-57 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAPXIL SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guselkumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosapent ethyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interleukin-10 SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
magnesium lysinate bis eicosapentaenoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMX-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic peptide for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Familial Adenomatous Polyposis - Dormant Projects
Familial Adenomatous Polyposis - Discontinued Products
Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases
Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx
Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis
Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference
May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis
Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis
Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps
Dec 10, 2018: Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis
Nov 19, 2018: Cancer Prevention Pharmaceuticals to present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018
Oct 22, 2018: Marc L. Tokars Joins Cancer Prevention Pharmaceuticals as Vice President of Clinical and Regulatory Affairs
Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance
Nov 21, 2017: Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Sep 18, 2017: FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, H1 2020
Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by GLW Pharma, H1 2020
Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, H1 2020
Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H1 2020
Familial Adenomatous Polyposis - Dormant Projects, H1 2020
Familial Adenomatous Polyposis - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Familial Adenomatous Polyposis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned
• Cancer Prevention Pharmaceuticals Inc
• Cellix Bio Pvt Ltd
• DNAlite Therapeutics Inc
• Emtora Biosciences
• FunPep Co Ltd
• GLW Pharma
• Johnson & Johnson
• Recursion Pharmaceuticals Inc
• Shanghai Haishi Biopharmaceutical Co Ltd
• Stemsynergy Therapeutics Inc
• TherapyX Inc
• Thetis Pharmaceuticals LLC